# Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers

> **NCT02631954** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 24 (actual)

## Conditions studied

- Aspergillus Infections
- Candida Infections
- Fungal Infections

## Interventions

- **DRUG:** Vorico Injection 200mg(Voriconazole)
- **DRUG:** Vfend®(Voriconazole) IV 200mg

## Key facts

- **NCT ID:** NCT02631954
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2015-10
- **Final completion:** 2015-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02631954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02631954, "Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02631954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*